Expression of cyclin D1 and cyclin E in urothelial bladder carcinoma detected in tissue chips using a quantum dot immunofluorescence technique

Shan,Guang; Tang,Tian

doi:10.3892/ol.2015.3436

Expression of cyclin D1 and cyclin E in urothelial bladder carcinoma detected in tissue chips using a quantum dot immunofluorescence technique

Authors:
- Guang Shan
- Tian Tang
View Affiliations

Affiliations: Department of Urologic Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China, Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China
Published online on: June 30, 2015 https://doi.org/10.3892/ol.2015.3436
Pages: 1271-1276
Copyright: © Shan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the expression of cyclin D1 and cyclin E in tissue chips of bladder cancer using quantum dots (QDs), as well as examine its clinicopathological significance. The QD‑based immunofluorescence tissue chemical technique was adopted to detect cyclin D1 and cyclin E expression in 75 tissue chips of human urothelial bladder carcinoma (including 70 cases of urothelial bladder carcinoma and 5 cases of cystitis), and its correlation with clinicopathological features was analyzed. The positive rates of cyclin D1 and cyclin E expression in urothelial bladder carcinoma were 68.6% (48/70) and 70.0% (49/70), respectively; however, no expression was observed in cystitis. Based on the results of statistical analysis, the difference in the positive rates of cyclin D1 and cyclin E expression between urothelial bladder carcinoma and cystitis was significant (P<0.05). QD staining and statistical analysis revealed that the expression of cyclin D1 and cyclin E in urothelial bladder carcinoma was significantly higher compared with that in cystitis (P<0.05). However, no statistically significant difference (P>0.05) in cyclin D1 expression was observed in relation to pathological stage, clinical stage or invasion of urothelial bladder carcinoma; however, there was a significant difference (P<0.05) in cyclin E expression with respect to these factors. These results demonstrated that overexpression of cyclin D1 may be an early event in the occurrence of urothelial bladder carcinoma. Cyclin D1 may play a role in the initial stage where cell proliferation is a necessary step, without invasion or metastasis. In addition, overexpression of cyclin E was correlated with the stage and depth of invasion of urothelial bladder carcinoma. In conclusion, the abnormal expression of cyclin D1 and cyclin E may be involved in the occurrence and development of urothelial bladder carcinoma.

View Figures

View References

1	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
2	Friedrich MG, Weisenberger DJ, Cheng JC, et al: Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. Clin Cancer Res. 10:7457–7465. 2004. View Article : Google Scholar : PubMed/NCBI
3	Yakasai A, Allam M and Thompson AJ: Incidence of bladder cancer in a one-stop clinic. Ann Afr Med. 10:112–114. 2011. View Article : Google Scholar : PubMed/NCBI
4	Vlahou A: Back to the future in bladder cancer research. Expert Rev Proteomics. 8:295–297. 2011. View Article : Google Scholar : PubMed/NCBI
5	Shan G and Xia Y: Expression and clinical significance of RECK and MT1-MMP in bladder urothelium carcinoma tissues. Chin J Cancer Prev Treat. 19:1722–1725. 2012.
6	Shan G, Shan S, Zhang X and Liu XH: Expression and clinical sigificance of cyclin G1 and cyclin G2 in transitional cell carcinoma of bladder. Chinese J Histochem Cytochem. 18:268–273. 2009.
7	Shan G and Tang T: Expression and clinical sigificance of ADO in transitional cell carcinoma of bladder. Chinese J Histochem Cytochem. 20:267–271. 2011.
8	Shan G and Tang T: Expression and clinical sigificance of tumor suppressor genes DPC4 and TGF-β1 in transitional cell carcinoma of bladder. Chinese J Histochem Cytochem. 20:491–495. 2011.
9	Shan G and Tang T: Expression and clinical sigificance of CD82/KAI1 in transitional cell carcinoma of bladder. Chinese J Histochem Cytochem. 22:185–188. 2013.
10	Shan G and Tang T: Expression and clinical significance of PSCA and mesothelin in transitional cell carcinoma of bladder. Chinese J Histochem Cytochem. 6:684–692. 2010.
11	Otieno S, Grace CR and Kriwacki RW: The role of the LH subdomain in the function of the Cip/Kip cyclin-dependent kinase regulators. Biophys J. 100:2486–2494. 2011. View Article : Google Scholar : PubMed/NCBI
12	Jirawatnotai S, Hu Y, Michowski W, et al: A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers. Nature. 474:230–234. 2011. View Article : Google Scholar : PubMed/NCBI
13	Makiyama K, Masuda M, Takano Y, et al: Cyclin E overexpression in transitional cell carcinoma of the bladder. Cancer Lett. 151:193–198. 2000. View Article : Google Scholar : PubMed/NCBI
14	Farley J, Smith LM, Darcy KM, et al Gynecologic Oncology Group: Cyclin E expression is a signifieant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: a Gynecologic Oncology Group study. Cancer Res. 63:1235–1241. 2003.PubMed/NCBI
15	Scuderi R, Palucka KA, Pokorvskaja K, et al: Cyclin E overexpression in relapsed adult acute lymphoblastic leukemias of B-cell lineage. Blood. 87:3360–3367. 1996.PubMed/NCBI
16	Eble JN, Sauter G, Epstein JI and Sesterhenn IA: World Health Organization Classification of TumorsPathology and Genetics of Tumors of the Urinary System and Male Genital Organs. IARC Press; Lyon: 2004
17	Sobin LH, Gospodarowicz M and Wittekind C: Urological tumoursTNM Classification of Malignant Tumors UICC International Union Against Cancer. 7th. Wiley-Blackwell; pp. 262–265. 2009
18	Chen H, Xue J, Zhang Y, Zhu X, Gao J and Yu B: Comparison of quantum dots immunofluorescence histochemistry and conventional immunohistochemistry for the detection of caveolin-1 and PCNA in the lung cancer tissue microarray. J Mol Hist. 40:261–268. 2009. View Article : Google Scholar
19	Tang T and Zhang DL: Study on extracellular matrix metalloproteinase inducer and human epidermal growth factor receptor-2 protein expression in papillary thyroid carcinoma using a quantum dot-based immunofluorescence technique. Exp Ther Med. 9:1331–1335. 2015.PubMed/NCBI
20	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar : PubMed/NCBI
21	Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin. 58:71–96. 2008. View Article : Google Scholar : PubMed/NCBI
22	Dhawan D, Ramos-Vara JA, Naughton JF, et al: Targeting folate receptors to treat invasive urinary bladder cancer. Cancer Res. 73:875–884. 2013. View Article : Google Scholar : PubMed/NCBI
23	Sylvester RJ, van der Meijden AP, Oosterlinck W, et al: Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 49:466–475; discussion. 475–477. 2006. View Article : Google Scholar : PubMed/NCBI
24	Amit D, Tamir S, Birman T, et al: Development of targeted therapy for bladder cancer mediated by a double promoter plasmid expressing diphtheria toxin under the control of IGF2-P3 and IGF2-P4 regulatory sequences. Int J Clin Exp Med. 4:91–102. 2011.PubMed/NCBI
25	Das SN, Khare P, Singh MK and Sharma SC: Correlation of cyclin D1 expression with aggressive DNA pattern in patients with tobacco-related intraoral squamous cell carcinoma. Indian J Med Res. 133:381–386. 2011.PubMed/NCBI
26	Remacle F and Levine RD: Quantum dots as chemical building blocks: elementary theoretical considerations. Chemphyschem. 2:20–36. 2001. View Article : Google Scholar : PubMed/NCBI
27	Yu WW, Chang E, Drezek R and Colvin VL: Water-soluble quantum dots for biomedical applications. Biochem Biophys Res Commun. 348:781–786. 2006. View Article : Google Scholar : PubMed/NCBI
28	Koole R, Mulder WJ, van Schooneveld MM, Strijkers GJ, Meijerink A and Nicolay K: Magnetic quantum dots for multimodal imaging. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 1:475–491. 2009. View Article : Google Scholar : PubMed/NCBI
29	Li J, Huang X, Xie X, Wang J and Duan M: Human telomerase reverse transcriptase regulates cyclin D1 and G₁/S phase transition in laryngeal squamous carcinoma. Acta Otolaryngol. 131:546–551. 2011. View Article : Google Scholar : PubMed/NCBI
30	Hwang CF, Cho CL, Huang CC, et al: Loss of cyclin D1 and p16 expression correlates with local recurrence in nasopharyngeal carcinoma following radiotherapy. Ann Oncol. 13:1246–1251. 2002. View Article : Google Scholar : PubMed/NCBI
31	Umekita Y, Ohi Y, Sagara Y and Yoshida H: Over expression of cyclin D1 predicts for poor prognosis in estrogen receptor-negative breast cancer patients. Int J Cancer. 98:415–418. 2002. View Article : Google Scholar : PubMed/NCBI
32	Stamatakos M, Palla V, Karaiskos I, et al: Cell cyclins: triggering elements of cancer or not? World J Surg Oncol. 8:1112010. View Article : Google Scholar : PubMed/NCBI
33	Freemantle SJ and Dmitrovsky E: Cyclin E transgenic mice: discovery tools for lung cancer biology, therapy and prevention. Cancer Prev Res (Phila). 3:1513–1518. 2010. View Article : Google Scholar : PubMed/NCBI
34	Musat M, Morris DG, Korbonits M and Grossman AB: Cyclins and their related proteins in pituitary tumourigenesis. Mol Cell Endocrinol. 326:25–29. 2010. View Article : Google Scholar : PubMed/NCBI
35	Jung YJ, Lee KH, Choi DW, et al: Reciprocal expressions of cyclin E and cyclin D1 in hepatocellular carcinoma. Cancer Lett. 168:57–63. 2001. View Article : Google Scholar : PubMed/NCBI
36	Pajalunga D and Crescenzi M: Regulation of cyclin E protein levels through E2F-mediated inhibition of degradation. Cell Cycle. 3:1572–1578. 2004. View Article : Google Scholar : PubMed/NCBI
37	Richter J, Wagner U, Kononen J, et al: High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer. Am J Pathol. 157:787–794. 2000. View Article : Google Scholar : PubMed/NCBI
38	Li JQ, Miki H, Ohmori M, et al: Expression of cyclin E and cyclin-dependent kinase 2 correlates with metastasis and prognosis in colorectal carcinoma. Hum Pathol. 32:945–953. 2001. View Article : Google Scholar : PubMed/NCBI
39	Donnellan R, Kleinschmidt I and Chetty R: Cyclin E immunoexpression in breast ductal cancinoma: pathologic correlations and prognostic implications. Hum Pathol. 32:89–94. 2001. View Article : Google Scholar : PubMed/NCBI
40	Zhu HX: Cyclin E and tumor. Chinese Medical Journal of Zhong Guo Yejin Gongye Yixue Zazhi. 20:86–88. 2003.(In Chinese).
41	Bales ES, Dietrich C, Bandyopadhyay D, et al: High levels of expression of p27KIPl and cyclin E in invasive primary malignant melanomas. J Invest Dermatol. 113:1039–1046. 1999. View Article : Google Scholar : PubMed/NCBI
42	Harwell RM, Porter DC, Danes C and Keyomarsi K: Processing of cyclin E differs between normal and tumor breast cells. Cancer Res. 60:481–489. 2000.PubMed/NCBI
43	Siu KT, Rosner MR and Minella AC: An integrated view of cyclin E function and regulation. Cell Cycle. 11:57–64. 2012. View Article : Google Scholar : PubMed/NCBI